Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 8/20 | 0.52 |
| ▸ | METAP2 | P50579 | 4/20 | 0.52 |
| ▸ | METAP1 | P53582 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.43 |
| ▸ | GCK | P35557 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6915949 | 0.90 | CBFB (0.54) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6915491 | 0.90 | CBFB (0.54) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6915445 | 0.89 | CBFB (0.55) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6915957 | 0.88 | CBFB (0.57) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6916466 | 0.86 | CBFB (0.50) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6916891 | 0.86 | CBFB (0.54) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6916422 | 0.86 | CBFB (0.54) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL1822351 | 0.85 | CBFB (0.55) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6915955 | 0.85 | CBFB (0.55) | CBFBMETAP2METAP1NPC1LMNA | |
| SCHEMBL6915845 | 0.85 | CBFB (0.50) | CBFBMETAP2METAP1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912336-B2 | Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912336-B2 | Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120245185-A1 | ARYL AND HETEROARYL SULFONES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245185-A1 | ARYL AND HETEROARYL SULFONES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011057208-A2 | ARYL AND HETEROARYL SULFONES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245185-A1 | ARYL AND HETEROARYL SULFONES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM4, GRIK4, GRM2 | CBFB 2172/4885METAP2 3608/4885METAP1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.